Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying - Aclaris Therapeutics (NASDAQ:ACRS)

　　The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the companys prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

　　Aclaris Therapeutics

• The Trade: Aclaris Therapeutics, Inc. ACRS 10% owner Braden Michael Leonard bought a total of 352,397 shares at an average price of $1.15. To acquire these shares, it cost around $405,894.
• What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
• What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.

　　RENN Fund

• The Trade: RENN Fund, Inc. RCG President and CEO Murray Stahl acquired a total of 184 shares at an average price of $1.74. To acquire these shares, it cost around $320.
• What's Happening:RENN Fund shares rose around 5% over the past month.
• What RENN Fund Does:RENN Fund Inc is active in the financial services domain.